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Multiple sclerosis is a chronic debilitating autoimmune disease of the central nervous system. The contribution of B cells in
the pathoetiology of MS has recently been highlighted by the emergence of rituximab, an anti-CD20 monoclonal antibody that
speciﬁcally depletes B cells, as a potent immunomodulatory therapy for the treatment of MS. However, a clearer understanding of
theimpactBcellshaveontheneuro-inﬂammatorycomponentofMSpathogenesisisneeded inordertodevelopnoveltherapeutics
whose aﬀects on B cells would be beneﬁcial and not harmful. Since T cells are known mediators of the pathology of MS, the goal
of this review is to summarize what is known about the interactions between B cells and T cells, and how current and emerging
immunotherapies may impact B-T cell interactions in MS.
1.Introduction
It has long been established that T cells are mediators of the
pathology of multiple sclerosis (MS) in both murine models
and patient studies [1–6]. Although, the impact of B cells
and their antibody products in mediating the pathology of
MS has long been considered [7–10], their contributions
have been more recently highlighted by the demonstration
that Rituximab, an anti-CD20 monoclonal antibody that
speciﬁcallydepletesBcells,wasapotentimmunomodulatory
therapy for the treatment of MS [11, 12]. More importantly,
however, the eﬃcacy of Rituximab in the treatment of
MS patients is independent of secreted antibody since
Rituximab does not aﬀect plasma cell frequencies or serum
and cerebrospinal ﬂuid (CSF) antibody levels [13]. Thus,
scientists in the ﬁeld have refocused their attention on the
possible roles of B cells in MS that are independent of
theirantibodysecreting function.This papersummarizes the
possible “antibody secretion-independent” roles ofB cellson
T cell activation and regulation, the relative impact of the
B cell subpopulations on T cell activation and regulation,
evidence that these mechanisms are altered in MS, and how
currentand emergingimmunotherapiesmayimpactB-Tcell
interactions in MS.
2.What Isknownaboutthe Consequencesof
B-T Cell Interactions?
It has long been assumed that B cells are unlikely to play
a signiﬁcant role as antigen-presenting cells (APCs) in the
induction of eﬀector T cells since human B cells are less
potent APCs in vitro on a per-cell basis compared to den-
dritic cells [14]. However, in 1982, investigators published
for the ﬁrst time that human B cells could present antigens
[15]. In fact, B cells are potent APCs in humans in vitro
in the context of both alloantigen [16, 17] and exogenous-
foreign-antigen [18] responses. Studies in mouse models
in which the B cells cannot secrete antibodies have further
highlighted the importance of antibody independent B cell
responses [19, 20]. These results demonstrated that B cells
are required for generating optimal primary and secondary
T cell responses and are implicated as APC in a number of2 Multiple Sclerosis International
disease models in the mouse including rheumatoid arthritis
and type 1 diabetes [21–23].
More recently, it has been demonstrated that activated B
cells are more eﬀective in activating T cells than their resting
or na¨ ıve counterparts in the mouse [24–26]. This ﬁnding has
been conﬁrmed with human B cells as well, since human
na¨ ıve B cell alloantigen presentation can be increased with
CpG-ODN stimulation [27]. Antigen-speciﬁc B cell APC
function can also be increased with CD40L stimulation [27–
31].
The most well-studied consequence of B-T cell inter-
actions, however, is the induction of T cell tolerance or
expansion of regulatory T cells [32–34]. For example, in
mice, antigen speciﬁc na¨ ıve B cells induce na¨ ıve T cells to
proliferateanddiﬀerentiateintoregulatoryTcells[35].HEL-
speciﬁc CD43− (na¨ ıve) B cells do not elicit T cell pro-
liferation or IL-2 and interferon-gamma (IFNγ)s e c r e t i o n ,
suggesting that they induce T cell tolerance [36]. In mouse
models, na¨ ıve B cells did not participate in T cell priming in
vivo,implicating na¨ ıve B cells as a source ofregulatory B cells
[25, 37, 38].
However, few have examined the role of memory B
c e l la n t i g e np r e s e n t a t i o ni nh u m a n s ,w h i c hi sac r u c i a l
consideration since memory B cells are antigen experienced.
Our group demonstrated that memory B cells from healthy
donors express suﬃcient levels of CD80 and HLA-DR to
operate as antigen presenting cells to induce antigen speciﬁc
T cell proliferation and IFNγ secretion [39]. Our group has
also found that memory B cells from these same healthy
donors also produce high concentrations of lymphotoxin-
alpha (LTα)i nc o m p a r i s o nt ot h e i rn a ¨ ıve counterparts.
Another group demonstrated that memory B cells from
healthy donors induce T cell proliferation in response to
glatiramer acetate (GA), a peptide mimic of the neuro-
antigen, myelin basic protein (MBP), with some indication
thatCD80expression isimportant forthisfunction[18].Ina
separatestudy[16],itwasdemonstratedthatrestingmemory
B cells from healthy donors elicit robust allogeneic T cell
proliferation that was signiﬁcantly inhibited by anti-CD80
and anti-CD86 antibodies in contrast to na¨ ıve B cells, which
were unable to stimulate allogeneic T cell proliferation. With
the exception of these three studies, memory B cell antigen
presentation in healthy donors has not been explicitly
examined.
Memory B cells from treatment na¨ ıve RRMS patients,
however, have the unique ability to present neuroantigens
to autologous T cells and generate a proliferative response
and IFNγ production [39]. Memory B cells from healthy
donors are unable to support T cell proliferation and IFNγ
production in response to neuroantigens. Taken together it
appears that memory B cells might directly contribute to T
cell activation by presenting neuro-antigens and secreting
cytokines that enhance the Th1/IFNγ producing T cell
subset.WearecurrentlytestingwhethermemoryBcellsfrom
treatment-exposed RRMSpatientsmaintaintheircapacityto
incite T cell activation in a neuroantigen speciﬁc manner.
These ﬁndings have generated considerable interest in
dissecting the mechanism of B-T cell interactions, especially
as they relate to the antigen experience of B cells. The
two primary antibody secretion independent ways that B
cells potentially impact T cell activation or regulation are
by (1) providing costimulatory signals through direct B-T
cell interactions and (2) cytokine secretion. The following
sections detail the primary surface molecules and secreted
factors that are thought to contribute to T cell activation or
regulation by B cells.
3.What TypesofSurfaceMolecules
Expressed by B CellsCouldBeInﬂuencing
TCe l lF un c ti o n ?
Figure 1 depicts aspects of the currently accepted model
of important B-T cell interactions [40, 41]. Interactions
between B7.1/B7.2 (CD80/CD86) expressed on B cells and
their ligands and CD28 and CTLA4 expressed on T cells
have long been studied in MS [42, 43], and much is
understood regarding the inﬂuence of these interactions on
T cell responses [44–46]. In fact, circulating CD80+ B cells
are increased during active relapse phases of MS, compared
to patients in remission or controls [47], suggesting that
this population may be involved during the active phase of
the disease. Importantly, others have demonstrated that a
subset of memory B cells, but not na¨ ıve B cells, express CD80
[16, 18]C D 8 6[ 16], and CD25, although this expression is
not necessarily concurrent [18, 48]. The impact of CD80
expression on B cells and their ability to activate T cells is
certainly of interest since the stimulation of memory T cells
is CD28 independent [49].
Interactions between MHCII, peptide, and the TCR are
certainlycentral toeﬀectiveB-Tcellcostimulation,especially
in the context of MS, in which HLA-DR haplotypes have a
strong association [50–52]. T cell proliferation in the pres-
ence of CD19+ B cells (containing both na¨ ıve and memory B
cells) activated with CD40L and antigen is reduced by ∼60%
i nt h ep r e s e n c eo fa n t i - H L A - D Ra n t i b o d i e s[ 28].
Interactions between CD40 expressed on B cells and
CD40 ligand (CD40L) expressed on T cells are also critical
to mount an eﬀective T cell response [53]. This consistent
observation led to the development of anti-CD40L biologics
to dampen T cell responses but became problematic due
to the increase in thromboembolic events associated with
these biologics, and the discovery that activated platelets
express CD40L [54, 55]. Anti-CD40 agonists, however, are
being developed for applications in tumor immunotherapy
to mobilize T cells in patients with cancer [56]. Yet it is
unclearwhattypesofTcellsaremobilizedbyCD40-activated
B cells. This is a critical point to consider since puriﬁed
B cells stimulated with one of these new CD40 agonists in
combination with CpG (a TLR9 agonist) secreted high levels
of both IL-6 and IL-10 [57, 58].
Interactions between OX40L expressed on APCs and
OX40 expressed on T cells have profound eﬀects on T cell
responses. For example, Wang et al. have reported that co-
culturing IFNγ-activated microglia from mouse brain tissue
with murine CD4+ T cells signiﬁcantly increased T cell pro-
liferation, which was readily blocked by the addition of anti-
OX40Linthecultures[59].Inhumans,exposureofhumanTMultiple Sclerosis International 3
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Figure 1: Important co-stimulatory molecules in B-T cell interactions.
cellsto OX40Lpreventsthe developmentofIL-10-producing
T cells [60] and IL-17 producing T cells [61]. Thus, biologics
that block or enhance these interactions may be useful
therapeutics for autoimmunity and infection, respectively,
and are currently being considered for development in these
arenas. However,theimpactofOX40-OX40LligationonB-T
cell interactions has not been formally investigated.
4.What Types of Secreted Factors Produced by
BCellsCouldBeInﬂuencingTCellFunction?
The inﬂuence of T cell derived cytokines in health and
disease has dominated scientiﬁc literature for at least 2
decades. However, it has become apparent that activated B
cells have a high capacity to produce both inﬂammatory
and regulatory cytokines [92]( T a b l e1). For example, recent
investigations have demonstrated that IL-10-producing B
cells have an immunomodulatory role in experimental
allergic encephalomyelitis (EAE), which is the mouse model
of MS [93, 94]. However, CD19+ B cell pools from MS
patients have a diminished capacity to produce IL-10 [95,
96], suggesting that the inﬂammatory responses in MS
patients may be partially attributable to a defect in IL-
10 production by B cells. In vitro activation of puriﬁed
na¨ ıve and memory B cells from the RRMS patient cohort
used in our studies using CD40L (as was done by [96]),
demonstrates that na¨ ıve B cells produced similar amounts
of IL-10 reported by [66, 95, 97], but memory B cells did
notproduceappreciableamountsofIL-10[39].Interestingly,
when we cultured na¨ ıve B cells with T cells in our B-T
cell culture system, we did not observe appreciable T cell
proliferation in response to neuro-antigens, suggesting that
the amount of IL-10 produced by na¨ ıve B cells from RRMS
patients may regulate T cell responses. In support of this
concept, IL-10 treatment of CD4 T cells from patients with
rheumatoid arthritis signiﬁcantly decreased the numbers of
Th17 cells in vitro [98].
So what pro-inﬂammatory cytokines do B cells generate
that have a high likelihood of eﬀecting T cell function in
response to neuro-antigens? LTα and tumor necrosis factor
alpha (TNF-α) are classic candidates of the TNF superfamily
with similar structure [99, 100]. Their expression by B cells
is required for germinal center formation [101]a n dt h e
migration of antigen-loaded myeloid dendritic cells (mDCs)
to follicles [102]. LTα is also required for the generation of
memory B cells and isotype switch [103]. LTα and TNF-
α are readily produced by activated memory B cells from
healthy donors [104], and T cells express receptors for these
cytokines [105]. Furthermore, TNFα and LTα levels are
increasedinMSlesionsandmediateoligodendrocytetoxicity
in vitro [106]. B cells from RRMS patients showed increased
LTα and TNFα and decreased IL-10 production in response
to polyclonal stimuli (CD40L and BCR crosslinking) in the
presence of a TLR9 agonist or IFNγ [107]. In fact, when
CD19+ cells are removed in vitro from peripheral blood
mononuclear (PBMC) cultures, CD4+ and CD8+ T cell
proliferation is decreased and may be due to a lack of B cells
secreting LTα and TNFα [107], which would support T cell
proliferation.
Transforming growth factor-beta (TGF-β)a n dI L - 6a r e
readily secreted by activated B cells as well [108], and there4 Multiple Sclerosis International
Table 1: Cytokines produced by B cells.
Cytokine eﬀects Demonstration
IL-10 Inhibits T cell proliferation, IFN-γ and IL-2 production
while enhancing Th2 responses [62–64]
Puriﬁed CD19+ peripheral human B cells produce IL-10 protein after
dual stimulation with CpG and CD40L [65]. MaximalIL-10
production was noted with CD40L alone, compared to dual
stimulationof BCR cross-link and CD40L [66]. IL-10 was secreted
primarily by na¨ ıve CD19+CD27− B cells [39].
TGF-β
Induces tolerance and inﬂammation-dependent
additional cytokine signals;IgA class switch and
dampening NK activity [67–69]; development of Th17
and Treg cells [70]
Human total CD19+ B cells produce TGF-β mRNA in response to
BCR cross-linking[71]. Anti-immunoglobulin treatment of murine
B cell lymphomas induces active TGF-β [71].
LT-α Required for the formation of germinal centers and
follicles, upregulation of adhesion molecules [72, 73]
Puriﬁed human CD19+ B cells produce signiﬁcant amounts of LT-α
after dual stimulation with CpG and CD40L [65]. Maximal
production was observed after dual stimulationof BCR cross-link
and CD40L [66]. LT-α was secreted primarily by memory
CD19+CD27+ B cells [39].
TNF-α
Increases IL-2 receptor and HLA-DR expression;
induces T cell proliferation and IFN-γ production
[74, 75]
Human CD19+ B cells produce TNF-α in response to CpG
stimulation alone or in combination with CD40L [65, 76], or dual
stimulationof BCR cross-link and CD40L [66]. TNF-α was secreted
primarily by memory CD19+CD27+ B cells [39, 77].
IL-12
Critical for Th1 development, induces IFNγ
production, enhances NK and CTL activity, inhibits
Th2 development, and inhibits IgE class switching [78]
Human total CD19+ B cells produce IL-12p70 in response to dual
stimulation with CpG and CD40L, but not in response to CpG (or
CD40L) alone [65].
IL-6
Mediates early inﬂammation;activates endothelium
a n da c t sa sg r o w t ha n dr e c r u i t m e n tf a c t o rf o r
lymphocytes [79–82]
Mediates early inﬂammation,activates endothelium, and acts as
growth and recruitment factor for lymphocytes [79–81].
IFN-γ Ampliﬁes IFN-γ production; activates CTL and NK;
critical for Th1 response [83, 84]
EBV-transformed B cell lines constitutively express IFN-γ as
measured by qPCR [85]. PMA or IL-2 stimulation of EBV or B cell
tumor lines induces IFN-γ [86].
IFN-α
Upregulates inﬂammatory cytokines [87]; implicated in
the pathogenesis of several inﬂammatoryautoimmune
diseases including RA and IBD [88–90]
Puriﬁed human CD19+ B cells produce IFN-α transcripts in response
to TLR8 agonist,but only in the ﬁrst 24 hours post-stimulation [91].
Interestingly IFN-β, another type 1 interferon, is used as a treatment
for RRMS.
is certainly much excitement regarding the ability of TGFβ
and IL-6 in combination to mediate Th17 cell activity since
Th17 cells are central to the inﬂammation associated with
EAE[1,109–114].However,theclassicroleofTGFβhasbeen
to induce tolerance in the immune system, and indeed, anti-
TGFβ treatment of mice led to worsening of EAE disease
and more severe clinical pathology in these mice [115].
TGFβ has been attempted ineﬀectively as a treatment for
progressive MS [116]. In vitro recombinant TGFβ decreased
neuroantigen-speciﬁc T cell frequency and IFNγ and IL-4
producing T cells from MS patients [117].
More recently, others have demonstrated that murine
Th17 cells can be generated by either IL-6 alone or IL-6
in combination with TGFβ, but only those Th17 cells that
had been generated with IL-6 alone are encephalitogenic
[1]. IL-6 is increased in the CSF of other inﬂammatory
neurological disorders including transverse myelitis (TM)
and neuromyelitis optica(NMO)[118, 119],in thelesions of
MS patients [120], and in some cases, correlates with relapse
or general neurodegenerationin the progressive phase [121].
However, IL-6 is not increased in the CSF of MS patients
and IL-6 levels do not correlate with other CSF parameters
including oligoclonal bands, pleocytosis or IgG index [118,
122,123].WhetherIL-6iscentraltothegenerationofhuman
Th17 cells remains under investigation [124, 125].
Even with confounding and often negative results of
other studies in MS, it has been suggested to use the IL-
6 receptor blocking antibody, Tocilizumab, as a therapeutic
agent. Interestingly, IL-6 is increased after treatment of MS
patients with IFNβ, suggesting that this pleiotropic cytokine
might not play an inﬂammatory pathogenic role in MS
as IL-6 can have both systemic and local eﬀects [126].
Because this cytokine diﬀers in its necessity for EAE, it
might represent an insurmountable task to go to trial due to
the uncertain/unpredictable nature of the outcome without
predictive animal models.
5. What Is the Effect of Immunotherapy on
BC e l lA P CF u n c ti o ni nM S ?
As discussed earlier in this paper, T cells from RRMS
patients treated with Rituximab had a poor response to
antigen stimulation, suggesting that the lack of B cells in
the periphery of these patients has a profound impact on T
cell activation. Interestingly, circulating memory B cells areMultiple Sclerosis International 5
Table 2: Possible impact of established and emerging therapies for MS on B cell function.
Therapeutic agent Description Impact on B-T interactions
Tysabri Blocking antibody to α4β1
integrin (VLA4)
VLA4 is required for extravasation of lymphocytes across the blood
brain barrier (BBB).A blockade of this adhesion molecule prevents
autoreactive B and T cells from entering the CNS, thus limiting
immune-mediated damage. CNS antigens are less available for
antigen presentation without migration of antigen presenting cells
(such as B cells) across the BBB.
MLN1202 CCR2 blocking antibody
Both B and T cells express CCR2, the receptor for MCP-1 [127].
Mouse studies show that MCP-1 is expressed in the microvessels
[128] and that it is increased in MS [129]. This blocking antibody
may abrogate leukocyte entrance into the CNS.
BAF312 and Fingolimod blocking antibodies for the S1P
receptor
These agents block egress of lymphocytes from secondary lymphoid
organs. This therapy should decrease lymphocytes entry into the
CNS. This mechanism is presumed to be similar to Tysabri.
Vitamin D3 Nutritional and environmental
nutrient
The vitamin D3 receptor is expressed on GC and na¨ ıve and memory
B cells [130]. Furthermore, Vitamin D3 reduces proliferative
responses of B cells, reduces antibody secretion and class switching,
inhibits maturation into memory and plasma phenotypes and
induces apoptosis, but does not modulate the expression of HLA-DR
or coreceptors [131]. Given these results, this therapy may have a
profound eﬀect on B cell activity in the context of MS.
CGP77116
Altered peptide ligand/mimetope
for a dominantantigenic
determinant of MBP (83–99)
CGP7716 will dampen the MBP-speciﬁc response by competing with
native MBP. MBP-speciﬁc B cells could take up the APL and present it
to T cells.
Glatiramer acetate (GA,
Cop1, Copaxone)
Random polymer comprised of
amino acids in a similarratio as
MBP
GA is known to skew the cytokine milieu toward a Th2 phenotype
[132]. The eﬀect of GA on B cell function is unknown.
also reduced in RRMS patients during mitoxantrone therapy
[96]a n dI F N β therapy [133]. IFNβ treatment decreases
MBP-elicited IFNγ and TNFα, but also decreases IL-10
and increases IL-6 [134]. Another study demonstrated that
IFNβ increases the expression of a phosphatase (SHP-1)
that negatively regulates inﬂammatory T cell signaling from
TNFα,I F N γ, IL-4, and IL-13 [135]. From these results, one
may speculate that the eﬀects of IFNβ on T cells modulate
their responsiveness to cytokine signals, some provided by
B cells. On the other hand, in vitro studies show that Th17
cells and associated cytokines (IL-23, TGFβ and IL-1β)w e r e
reduced, while anti-inﬂammatory cytokines produced by
B cells and dendritic cells were increased. Reemerging B
cells from RRMS patients treated with mitoxantrone therapy
recovered the ability to produce IL-10 [107], but again, the
impact of these IL-10-secreting B cells on neuroantigen-
speciﬁc T cell responses was not tested. Table 2 lists other
current and emerging therapies and their possible impact on
B cell function and emphasizes the urgent need to investigate
how these drugs may aﬀect B-T cell interactions in the
patients receiving them.
In summary, the inﬂuence of B cells on T cell function
is only beginning to be realized. Further investigations are
required in order to fully comprehend the impact of current
and emerging therapeutics on B cell responses, which in
turn, may have profound impact on T cell function in
autoimmune diseases such as MS.
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